Table 1 Demographic and clinical characteristics of patients.
From: Estimated cost of treating hospitalized COVID-19 patients in Saudi Arabia
Characteristic | Patients (n = 287) n (%) |
|---|---|
Age, Mean ± SD | 59.2 ± 15.9 |
Gender | |
Male | 158 (55) |
Female | 129 (45) |
Pre-existing disease* | |
None | 58 (20.2) |
Neurological Disease | 18 (6.3) |
Cardiovascular disease | 153 (53.3) |
GI disease | 7 (2.4) |
Renal disease | 56 (19.5) |
Respiratory disease | 30 (10.5) |
Malignancy disease | 6 (2.1) |
Endocrine disease | 27 (9.4) |
Diabetes mellitus | 155 (54) |
Hematological disease | 14 (4.9) |
*A patient could have more than one comorbidity | |
Disease severity | |
Mild–Moderate | 60 (20.9) |
Severe | 148 (51.6) |
Critically ill | 79 (27.5) |
Treatment medications* | |
Antiviral | 207 (72.1) |
Antibiotic | 266 (92.7) |
Antifungal | 9 (3.1) |
Immunomodulators | 80 (27.9) |
Anticoagulants | 268 (93.4) |
Steroid | 119 (41.5) |
Immunosuppressant | 10 (3.5) |
Tocilizimub | 19 (6.6) |
*A patient can receive more than one line of treatment | |
Length of Hospital stay | Median, IQR, 8 (9) |
Mean (SE), (12.24 (0.77) | |
Clinical outcome | |
Alive | 240 (83.6) |
Died | 47 (16.4) |
